Ikena Oncology (IMA) - מזומן למניה

Cash per share dynamics exhibit volatility, with the current figure standing at 10.12. These fluctuations are driven by the risk of drug trial failures and the necessity for new equity offerings. Stability is supported by the non-cyclical nature of oncology biotech, which remains independent of GDP. The absence of raw material supply disruptions, thanks to insurance buffers, minimizes operational downtime, ensuring the resilience of ImageneBio Inc (IMA) financial reserves.
פילוחי מדדים מקיפים ואנליטיקה עבור Ikena Oncology (IMA)

This indicator determines the share of net liquid assets per security, reflecting the real value of the business's cash backing. For ImageneBio Inc (IMA), this resource is critical for the creation of high-tech oncological biomarkers. By analyzing the trend of the cash cushion per share, an investor assesses the company's ability to fund costly targeted therapy research. A stable liquidity level confirms the brand's financial stability, which minimizes bankruptcy risks during long-term drug development.